Drug DevelopmentPositive data for lacutamab in Sezary syndrome was reported, indicating potential treatment advancements in this area.
Regulatory ProgressThe FDA has lifted the partial clinical hold on lacutamab, clearing the path for continued development.
Safety ProfileA fatality previously concerning investors is now determined to be unrelated to lacutamab, suggesting a better safety profile than expected.